Zarogoulidis Paul, Kosmidis Christoforos, Perdikouri Eleni-Isidora, Hohemforst-Schmidt Wolfgang, Sardeli Chrisanthi
Pulmonary Department, General Clinic Euromedica, Thessaloniki, Greece.
3rd Surgery Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Respir Med Case Rep. 2022 Sep 15;39:101741. doi: 10.1016/j.rmcr.2022.101741. eCollection 2022.
Nowadays immunotherapy is considered the tip of the arrow as treatment for non-small cell lung cancer for inoperable patients. Programmed death-ligand 1 is considered a valuable marker for the success of immunotherapy. The higher the score ≥50% the more successful the treatment will be. However; previous studies have presented favorable data even for those patients where the programmed death-ligand 1 was ≤50% or even 0%, therefore it can be administered as first line treatment in these patients with the addition of chemotherapy or radiotherapy. Other treatment modalities are tested as surrogates like gene therapy with immunotherapy to improve the results in patients with programmed death-ligand 1 was ≤50% or even 0%. The main issue for these patients is an adverse effect pneumonitis, in case we will present the valuable method of lung parenchyma sampling with cryobiopsy for early diagnosis of immunotherapy induced pneumonitis.
如今，免疫疗法被视为治疗无法手术的非小细胞肺癌患者的“箭头尖端”疗法。程序性死亡配体1被认为是免疫疗法成功的一个有价值的标志物。评分≥50%越高，治疗就越成功。然而，先前的研究表明，即使对于那些程序性死亡配体1≤50%甚至为0%的患者，也有良好的数据，因此在这些患者中可联合化疗或放疗作为一线治疗。其他治疗方式也作为替代方法进行测试，如免疫疗法联合基因疗法，以改善程序性死亡配体1≤50%甚至为0%的患者的治疗效果。这些患者的主要问题是不良反应肺炎，在此我们将介绍通过冷冻活检进行肺实质采样以早期诊断免疫疗法诱导肺炎的有价值方法。
